LGND earnings analysis
What we found in LGND's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 2026 operating results showed a favorable trend, with revenue of $63.693 million and diluted EPS of $2.37, both materially above Q1 2026 and Q2 2025 levels. The company also completed a $60.0 million share repurchase funded partly by the 2031 Notes offering, while the Nexterone litigation was dismissed without prejudice. However, the filing highlights significant new risks from XOMA integration, obligations under the 2030 and 2031 Notes, royalty buyout provisions and the expanding Viking litigation.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue and EPS improved sharply
- Q2 2026 revenue was $63.693 million, up approximately 22% from $52 million in Q1 2026 and approximately 33% from $48 million in Q2 2025. Diluted EPS was $2.37 versus negative $0.67 in Q1 2026 and $0.24 in Q2 2025.
- Share repurchase supported by note proceeds
- The company repurchased 228,859 shares at $262.17 per share in June 2026, using approximately $60.0 million of net proceeds from the 2031 Notes offering and cash on hand.
- New 2031 convertible financing
- The company issued 0.00% Convertible Senior Notes due 2031, adding a new financing source alongside its 2030 Notes and supporting liquidity for strategic activity.
- Nexterone litigation concluded
- In the Captisol-enabled Nexterone litigation, the parties submitted a joint dismissal stipulation on June 16, 2026, and the court entered the dismissal without prejudice on July 23, 2026.
- CyDex secured partial pleadings ruling
- The Delaware court denied Bexson’s motion for judgment on the pleadings and granted part of CyDex’s motion on April 22, 2026; the matter is expected to proceed to discovery.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Viking cross-complaint adds litigation exposure
- Ligand’s Viking dispute expanded after Viking filed a cross-complaint on July 2, 2026 asserting 3 causes of action, including declaratory relief and breach of contract. Ligand states that the matter is at an early stage and that potential losses cannot be estimated.
- XOMA integration execution risk
- The company added an XOMA Acquisition integration risk, stating that integration of operations, personnel, systems and the royalty portfolio could be more costly or time-consuming than anticipated and could materially adversely affect results and cash flows.
- Debt service and refinancing risk
- The company added a debt-servicing risk covering its 2030 Notes and 2031 Notes, including potential cash repurchases upon specified events and possible dilution if the notes convert. The filing also states that insufficient operating cash flow could require asset sales, debt restructuring or additional equity or debt financing.
- Royalty buyout rights may reduce revenue
- Certain royalty and milestone arrangements permit counterparties to reduce, buy down or buy out future obligations for predetermined amounts that may be less than the net present value of future royalties, potentially reducing recurring revenue.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $2.37
What they said about what is next.
The supplied 10-Q text does not include a quantitative outlook. Prior company guidance was reported separately as revenue of $270 million-$310 million and EPS of $8.50-$9.50, but no confirmation or change is provided in the supplied filing excerpt.
The filing reads better than the one before it.
What came before.
- 10-Q · May 8, 2026
- Ligand Pharmaceuticals posted Q1 2026 results showing revenue of $51.7 million, reflecting a 14% increase year-over-year but below estimates by approximately 12%. Gross margins remain robust at 95%, and the company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LGND makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever